Abstracts

THERAPEUTIC VACCINATION OF SHIV-INFECTED, ART-SUPPRESSED INFANT RHESUS MACAQUES

Background: Breastfeeding based HIV transmission accounts for the majority of new pediatric HIV infections. Antiretroviral therapy (ART) fails to eradicate HIV reservoirs, which lead to rapid viral rebound following ART interruption. Therapeutic interventions effective in eliminating viral reservoirs and thereby delaying or preventing viral rebound in the absence of ART would be highly valuable for…

VIRAL RESERVOIR LANDSCAPE OF CHILDREN WITH HIV IN BOTSWANA TREATED WITH DUAL bNAbs

Background: To evaluate possible alternatives to ART among children living with HIV, the Tatelo clinical trial administered two broadly-neutralizing antibodies to children in Botswana with HIV clade C infection who had initiated ART at birth. Here we describe a high-resolution, cross-sectional and longitudinal analysis of the proviral reservoir landscape in Taleo participants. Methods: Children were…

VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA

Background: Persistent low-level HIV-1 viremia (pLLV) can occur in people with HIV despite high adherence to antiretroviral therapy (ART), without significant drug resistance, and due to unclear mechanisms. Methods: We enrolled 8 ART-treated participants with ≥3 HIV-1 RNA levels between 40-1000 copies/mL over 24 months. Near-full length sequencing of the proviruses and pol-env sequencing of…

PROVIRUSES IN SELF-REACTIVE CD4+ T CELLS ARE A COMMON SOURCE OF RESIDUAL HIV VIREMIA

Background: Despite adherence to ART, some individuals experience persistent nonsuppressible HIV viremia (NSV, VL >20 cps/mL) due to clones of infected CD4+ T cells producing virus. However, mechanisms driving constant expression of these proviruses are not understood. We hypothesized that infected clones cross-reactive to ubiquitous self-antigens could produce residual viremia. Methods: We characterized residual viremia…

SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS

Background: HIV-1 reservoir cells persist lifelong despite ART but may be vulnerable to host immune responses that could be exploited for HIV-1 cure strategies. Here, we used a novel single-cell, next-generation sequencing approach for the direct ex vivo phenotypic profiling of individual HIV-1 infected memory CD4 (mCD4) T cells from peripheral blood (PB) and lymph…

THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL

Background: Toll-like receptor 9 (TLR9) agonists stimulate innate antiviral immunity, prime adaptive immune responses and reverse latency in people with HIV-1 infection (PWH). Further, broadly neutralizing anti-HIV-1 antibodies (bNAbs) can boost HIV-specific immunity and enhance killing of infected cells through Fc-dependent mechanisms. Here, we evaluated the impact of the TLR9 agonist Lefitolimod and dual bNAb…